儿童接种MenACWY-CRM后抗体持久性与加强应答:两种检测方法评估
这项3b期开放标签多中心扩展试验评估了婴儿期接种MenACWY-CRM后抗体持久至4年及60月龄加强剂应答。结果显示已免疫儿童抗体持久性高于未免疫儿童,A群hSBA滴度≥8比例低(6-25%),C群中等(27-43%),Y群(69-74%)和W群(56-69%)较高;加强剂后≥96%已免疫儿童和≥73%未免疫儿童对各群hSBA滴度≥8,耐受良好。
要点
- 婴儿期接种MenACWY-CRM后4年抗体持久性对C、W、Y群中等,对A群较低。
- 60月龄加强剂在各初免疫苗程序下均诱导对所有血清群的强免疫应答。
- 加强剂耐受良好,未发现安全性问题。
核心结论
- 婴儿/幼儿期基础接种MenACWY-CRM后,对C、W和Y群抗体持久性中等,可持续至末次基础剂量后4年。
- 无论基础免疫程序如何,60月龄加强剂对所有血清群均诱导强免疫应答且耐受良好。
研究设计与样本
- 3b期、开放标签、多中心扩展试验(NCT01148017)。
- 评估203名健康60月龄儿童,分别于婴儿期接种4剂(ACWY-4组)或12/13和15月龄接种2剂或18月龄接种1剂(ACWY-2组)。
- 对224名已免疫和45名未免疫60月龄儿童接种MenACWY-CRM,评估1个月后安全性和抗体应答。
主要发现
- 两种检测方法测得的抗体持久性在已免疫儿童中高于未免疫60月龄儿童。
- 已免疫儿童hSBA滴度≥8的比例:A群6-25%,C群27-43%,Y群69-74%,W群56-69%。
- 所有血清群hSBA抗体几何平均滴度(GMTs)在ACWY-2组倾向于高于ACWY-4组。
- 加强/单剂后,≥96%已免疫儿童和≥73%未免疫儿童对各血清群hSBA滴度≥8,已免疫儿童hSBA GMTs更高。
- 加强剂耐受良好,未发现安全性问题;rSBA与hSBA滴度之间总体无相关性。
临床怎么用
- 婴儿期接种MenACWY-CRM后4年抗体持久性对A群较低,对C、W、Y群中等,提示需关注加强免疫。
- 60月龄加强剂可有效提升各血清群抗体水平,且耐受良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The quadrivalent meningococcal conjugate vaccine MenACWY-CRM has been shown to be immunogenic and well-tolerated in infants and toddlers. We evaluated antibody persistence for up to 4 years after vaccination with MenACWY-CRM in the first years of life and response to a booster dose administered at 60 months of age. METHODS: This was phase 3b, open-label, multicenter extension trial (NCT01148017). We assessed by hSBA and rSBA the persistence of antibody responses to serogroups ACWY in 203 healthy 60-month-olds receiving 4 doses of MenACWY-CRM during infancy (ACWY-4 group), or 2 doses at 12/13 and 15 months or 1 dose at 18 months of age (ACWY-2 group). We administered a MenACWY-CRM dose to 224 primed and 45 naïve 60-month-olds and evaluated safety and antibody response 1 month later. RESULTS: Antibody persistence measured by both assays was higher in primed than naïve 60-month-olds. The percentages of primed children with hSBA titers ≥8 was low for serogroup A (6-25%) and moderate for serogroups C (27-43%), Y (69-74%) and W (56-69%). For all serogroups, hSBA antibody geometric mean titers (GMTs) tended to be higher in the ACWY-2 than the ACWY-4 group. Post-booster/single dose, ≥96% of primed and ≥73% of naïve children had hSBA titers ≥8 against each serogroup, and hSBA GMTs were higher in primed children. The booster dose was well-tolerated and no safety concern was identified. We further assessed persistence using rSBA across different age groups and detected no overall correlation between rSBA and hSBA titers. CONCLUSIONS: Primary vaccination of infants/toddlers with MenACWY-CRM resulted in moderate antibody persistence against serogroups C, W and Y for up to 4 years after the last priming dose. Regardless of priming schedule, a MenACWY-CRM booster dose at 60 months of age induced a robust immune response against all serogroups and was well-tolerated in all children.
引用
- Klein NP, Block SL, Essink B, et al. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. Vaccine. 2019. PMID: 31279564. doi:10.1016/j.vaccine.2019.06.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。